08/09/22 4:33 PMNasdaq : KOD earningsKodiak Sciences Announces Second Quarter 2022 Financial Results and Recent Business HighlightsKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resultsRHEA-AIpositive
08/08/22 6:30 AMNasdaq : KOD clinical trialKodiak Sciences Reports Positive Topline Results from BEACON Phase 3 Study of Tarcocimab Tedromer (KSI-301) in Patients with Retinal Vein OcclusionTarcocimab tedromer (KSI-301) dosed every two months met the primary endpoint of non-inferior visual acuity gains compared to aflibercept dosed every month First anti-VEGF therapy to achieve non-inferiority in visual acuity gains while doubling the treatment interval in patients with RVO TarcocimabRHEA-AIpositive
08/05/22 4:30 PMNasdaq : KOD clinical trialKodiak Sciences Completes Enrollment in GLOW Phase 3 Clinical Trial of Tarcocimab Tedromer (KSI-301) in Patients with Non-Proliferative Diabetic RetinopathyKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in itsRHEA-AIneutral
05/27/22 8:00 AMNasdaq : KOD conferencesKodiak Sciences to Present at the Jefferies Global Healthcare ConferencePALO ALTO, Calif. , May 27, 2022 Kodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, announced today that management will present at the Jefferies GlobalRHEA-AIneutral
05/19/22 8:00 AMNasdaq : KOD Grand Opening of Kodiak Sciences' Purpose-built Bioconjugation Facility to Support Potential Commercial Manufacture of KSI-301, an Antibody Biopolymer Conjugate for Retinal DiseasesPurpose-built bioconjugation facility in Lonza's Ibex ® Dedicate Biopark in Visp, Switzerland to support the potential commercial launch of Kodiak's lead product candidate KSI-301 for high-prevalence retinal diseases The opening ceremony took place on May 17, 2022 following mechanical completion ofRHEA-AIpositive
05/10/22 4:10 PMNasdaq : KOD earningsKodiak Sciences Announces First Quarter 2022 Financial Results and Recent Business HighlightsKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resultsRHEA-AIpositive
04/29/22 5:30 AMNasdaq : KOD clinical trialKodiak Sciences Announces Presentation of KSI-301 Phase 2b/3 Study Data in wet AMD at Upcoming Research ConferencesKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that presentations of clinical studyRHEA-AIneutral
03/01/22 4:10 PMNasdaq : KOD earningsKodiak Sciences Announces Fourth Quarter and Full Year 2021 Financial Results and Recent Business HighlightsKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today reported business highlights and financial resultsRHEA-AIneutral
02/23/22 6:00 AMNasdaq : KOD clinical trialKodiak Sciences Announces Top-Line Results from its initial Phase 2b/3 Study of KSI-301 in Patients with Neovascular (Wet) Age-Related Macular DegenerationKodiak Sciences Inc. (Nasdaq: KOD) today announced top-line results from its randomized, double-masked, active comparator-controlled Phase 2b /3 clinical trial evaluating the efficacy, durability and safety of KSI-301, a novel antibody biopolymerRHEA-AIneutral
02/03/22 5:30 AMNasdaq : KOD clinical trialKodiak Sciences Completes Enrollment in GLEAM and GLIMMER Phase 3 Clinical Trials of KSI-301 in Patients with Diabetic Macular EdemaKodiak Sciences Inc. (Nasdaq: KOD), a biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat high prevalence retinal diseases, today announced that it has completed enrollment in itsRHEA-AIneutral